2018
Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models
Weihofen A, Liu Y, Arndt JW, Huy C, Quan C, Smith BA, Baeriswyl JL, Cavegn N, Senn L, Su L, Marsh G, Auluck P, Montrasio F, Nitsch RM, Hirst WD, Cedarbaum JM, Pepinsky R, Grimm J, Weinreb PH. Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models. Neurobiology Of Disease 2018, 124: 276-288. PMID: 30381260, DOI: 10.1016/j.nbd.2018.10.016.Peer-Reviewed Original ResearchConceptsΑ-Syn pathologyParkinson's diseaseΑ-synDisease progressionMouse modelPrevention of PDPhase 2 clinical trialPD mouse modelPD brain tissueDisease modelsDopamine transporter densityParkinson's disease modelΑ-synuclein antibodyPromising therapeutic approachDifferent mouse modelsHealthy elderly individualsΑ-syn fibrilsEpitope mapping studiesDopaminergic terminalsRecombinant α-synPreclinical dataClinical trialsTherapeutic approachesMotor impairmentElderly individualsTargeted Therapies for Parkinson's Disease: From Genetics to the Clinic
Sardi SP, Cedarbaum JM, Brundin P. Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic. Movement Disorders 2018, 33: 684-696. PMID: 29704272, PMCID: PMC6282975, DOI: 10.1002/mds.27414.Peer-Reviewed Original ResearchConceptsParkinson's diseaseGreat unmet medical needDisease-modifying treatmentsNew therapeutic approachesUnmet medical needClinical stageClinical trialsRelentless progressionTherapeutic approachesPotential therapyClinical developmentTherapeutic paradigmMedical needDiseaseGenetic variantsPD geneticsNew arsenalTreatmentGenetic discoveriesKey outstanding questionsTherapySymptomsPathologyProgressionTrials
1990
Pharmacokinetic and Pharmacodynamic Considerations in Management of Motor Response Fluctuations in Parkinson's Disease
Cedarbaum J. Pharmacokinetic and Pharmacodynamic Considerations in Management of Motor Response Fluctuations in Parkinson's Disease. Neurologic Clinics 1990, 8: 31-49. PMID: 2181267, DOI: 10.1016/s0733-8619(18)30372-4.Peer-Reviewed Original ResearchConceptsMotor response fluctuationsResponse fluctuationsLevodopa-related fluctuationsSynthetic dopamine agonistsPlasma levodopa levelsMajority of patientsPharmacokinetics of levodopaSuch treatment approachesBrain dopaminergic activityLong-term treatmentBrain dopamine levelsRapid systemic clearanceAnti-Parkinson agentsLevodopa levelsDopamine agonistsPharmacodynamic consequencesPharmacodynamic considerationsSystemic clearanceAdvanced PDDopamine levelsDopaminergic activityTherapeutic approachesParkinson's diseaseTreatment approachesGalenic formulation